74 related articles for article (PubMed ID: 15892710)
1. Editorial: melanomas and Wnts.
Goding C
Pigment Cell Res; 2005 Jun; 18(3):149. PubMed ID: 15892710
[No Abstract] [Full Text] [Related]
2. Histone deacetylase inhibitors and malignant melanoma.
Boyle GM; Martyn AC; Parsons PG
Pigment Cell Res; 2005 Jun; 18(3):160-6. PubMed ID: 15892712
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
Wilking MJ; Singh C; Nihal M; Zhong W; Ahmad N
Arch Biochem Biophys; 2014 Dec; 563():94-100. PubMed ID: 24751483
[TBL] [Abstract][Full Text] [Related]
4. Overcoming melanoma drug resistance through metabolic targeting?
Smalley KS
Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
[No Abstract] [Full Text] [Related]
5. N-(3,5-dimethylphenyl)-3-methoxybenzamide (A(3)B(5)) targets TRP-2 and inhibits melanogenesis and melanoma growth.
Lee EJ; Lee YS; Hwang S; Kim S; Hwang JS; Kim TY
J Invest Dermatol; 2011 Aug; 131(8):1701-9. PubMed ID: 21525883
[TBL] [Abstract][Full Text] [Related]
6. Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Essa S; Reichrath S; Mahlknecht U; Montenarh M; Vogt T; Reichrath J
Anticancer Res; 2012 Jan; 32(1):383-9. PubMed ID: 22213330
[TBL] [Abstract][Full Text] [Related]
7. The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells.
Wiersma VR; de Bruyn M; van Ginkel RJ; Sigar E; Hirashima M; Niki T; Nishi N; Samplonius DF; Helfrich W; Bremer E
J Invest Dermatol; 2012 Sep; 132(9):2302-5. PubMed ID: 22572821
[No Abstract] [Full Text] [Related]
8. Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Melnikova VO; Bar-Eli M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):505-6. PubMed ID: 18713130
[No Abstract] [Full Text] [Related]
9. Endothelin-1 induces CXCL1 and CXCL8 secretion in human melanoma cells.
Mangahas CR; dela Cruz GV; Friedman-Jiménez G; Jamal S
J Invest Dermatol; 2005 Aug; 125(2):307-11. PubMed ID: 16098041
[TBL] [Abstract][Full Text] [Related]
10. Targeting multiple key signaling pathways in melanoma using leelamine.
Gowda R; Madhunapantula SV; Kuzu OF; Sharma A; Robertson GP
Mol Cancer Ther; 2014 Jul; 13(7):1679-89. PubMed ID: 24688050
[TBL] [Abstract][Full Text] [Related]
11. TGF-β may control the switch between tumorigenic growth and "stem cell/mesenchymal" potentially drug-resistant states.
Bordelon JR; Grichnik JM
Dermatol Ther; 2015; 28(3):177-8. PubMed ID: 25649199
[No Abstract] [Full Text] [Related]
12. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
Karagiannis TC; El-Osta A
Leukemia; 2007 Jan; 21(1):61-5. PubMed ID: 17109024
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of 5-fluorouracil on human skin melanocytes and malignant melanoma cells in vitro.
Tsuji T; Karasek MA
Acta Derm Venereol; 1986; 66(6):474-8. PubMed ID: 2433865
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Kobayashi Y; Ohtsuki M; Murakami T; Kobayashi T; Sutheesophon K; Kitayama H; Kano Y; Kusano E; Nakagawa H; Furukawa Y
Oncogene; 2006 Jan; 25(4):512-24. PubMed ID: 16186804
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Daud AI; Dawson J; DeConti RC; Bicaku E; Marchion D; Bastien S; Hausheer FA; Lush R; Neuger A; Sullivan DM; Munster PN
Clin Cancer Res; 2009 Apr; 15(7):2479-87. PubMed ID: 19318485
[TBL] [Abstract][Full Text] [Related]
16. Reactive oxygen species may have antitumor activity in metastatic melanoma.
Tuma RS
J Natl Cancer Inst; 2008 Jan; 100(1):11-2. PubMed ID: 18159075
[No Abstract] [Full Text] [Related]
17. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.
Peltonen K; Kiviharju TM; Järvinen PM; Ra R; Laiho M
Pigment Cell Res; 2005 Jun; 18(3):196-202. PubMed ID: 15892716
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
[TBL] [Abstract][Full Text] [Related]
19. American Association for Cancer Research--96th Annual Meeting. Targeting the cell cycle and HDAC inhibitors.
Phillips T; Collins T; Davies J
IDrugs; 2005 Jun; 8(6):450-3. PubMed ID: 15906184
[No Abstract] [Full Text] [Related]
20. Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Shin H; Kim JH; Lee YS; Lee YC
Int J Oncol; 2012 May; 40(5):1533-42. PubMed ID: 22246241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
